Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Savara Inc (NQ: SVRA ) 4.515 -0.195 (-4.14%) Streaming Delayed Price Updated: 3:44 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 645,785 Open 4.630 Bid (Size) 4.510 (7) Ask (Size) 4.520 (17) Prev. Close 4.710 Today's Range 4.500 - 4.748 52wk Range 3.115 - 5.700 Shares Outstanding 114,066,080 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock June 28, 2024 From Savara Inc. Via Business Wire Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? June 26, 2024 Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant... Via Benzinga Performance YTD +3.32% +3.32% 1 Month +17.89% +17.89% 3 Month -5.74% -5.74% 6 Month +5.74% +5.74% 1 Year +39.35% +39.35% More News Read More Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday June 26, 2024 Via InvestorPlace SVRA Stock Earnings: Savara Misses EPS for Q1 2024 May 09, 2024 Via InvestorPlace SVRA Stock Earnings: Savara Beats EPS for Q4 2023 March 07, 2024 Via InvestorPlace Savara Inc. (NASDAQ: SVRA) Making Surprising Moves in Monday Session February 26, 2024 Via Investor Brand Network Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) June 26, 2024 From Savara Inc. Via Business Wire Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) June 25, 2024 From Savara Inc. Via Business Wire 3 Penny Stocks Poised for Major Upside Over the Next 5 Years June 19, 2024 Via InvestorPlace 3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition June 11, 2024 Via InvestorPlace Savara to Present at the Jefferies Global Healthcare Conference May 29, 2024 From Savara Inc. Via Business Wire Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 May 19, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant May 16, 2024 From Savara Inc. Via Business Wire Savara Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Savara Inc. Via Business Wire Savara to Present at the Citizens JMP Life Sciences Conference May 07, 2024 From Savara Inc. Via Business Wire Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 April 08, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant March 22, 2024 From Savara Inc. Via Business Wire Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update March 07, 2024 From Savara Inc. Via Business Wire Savara to Present at the Barclays 26th Annual Global Healthcare Conference March 06, 2024 From Savara Inc. Via Business Wire Savara Announces New Employment Inducement Grant February 02, 2024 From Savara Inc. Via Business Wire Savara to Present at Two Upcoming Healthcare Conferences January 31, 2024 From Savara Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session January 16, 2024 Via Benzinga Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday January 02, 2024 Via Benzinga Topics Stocks Exposures US Equities Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) December 21, 2023 From Savara Inc. Via Business Wire Savara Added to the NASDAQ Biotechnology Index December 20, 2023 From Savara Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
